$15.43
0.47[3.14%]
At close: Apr 26
$15.43
0[0.00%]
After Hours: 4:00PM EDT
Denali Therapeutics
(NASDAQ:DNLI)Latest News for Denali Therapeutics Stock (NASDAQ:DNLI)
Denali Therapeutics Stock (NASDAQ: DNLI)
Categories: All
Tuesday, April 09, 2024
Friday, March 22, 2024
Thursday, February 29, 2024
Wednesday, February 28, 2024
- 4 Analysts Assess Denali Therapeutics: What You Need To KnowBenzinga Insights - Feb 28, 2024, 2:00PM
- HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $95Benzinga Newsdesk - Feb 28, 2024, 12:27PM
- Wedbush Reiterates Outperform on Denali Therapeutics, Maintains $31 Price TargetBenzinga Newsdesk - Feb 28, 2024, 7:50AM
Tuesday, February 27, 2024
- Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Feb 27, 2024, 1:18PM
- Denali Therapeutics shares are trading higher after the company announced $500 million in private placement equity financing and reported Q4 financial results.Benzinga Newsdesk - Feb 27, 2024, 11:03AM
- Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Feb 27, 2024, 10:27AM
- Denali Therapeutics: Q4 Earnings InsightsBenzinga Insights - Feb 27, 2024, 9:00AM
- Denali Therapeutics Sees FY24 Operating Expenses Less Than Or Equal To 2023; Expects Cash Runway To Extend Into 2028Benzinga Newsdesk - Feb 27, 2024, 8:21AM
- Denali Therapeutics Q4 2023 GAAP EPS $(0.86) Misses $(0.81) EstimateBenzinga Newsdesk - Feb 27, 2024, 8:18AM
- Denali Therapeutics Announces $500M Private Placement Equity FinancingBenzinga Newsdesk - Feb 27, 2024, 8:03AM
Thursday, February 22, 2024
Friday, February 16, 2024
- Denali Therapeutics shares are trading lower after the company announced that the Phase 2 HIMALAYA study evaluating SAR443820/DNL788 in participants with ALS did not meet its primary endpoint.Benzinga Newsdesk - Feb 16, 2024, 9:12AM
- Denali Therapeutics Was Informed By Its Partner Sanofi That The Phase 2 HIMALAYA Study Evaluating SAR443820/DNL788 In Participants With Amyotrophic Lateral Sclerosis Did Not Meet The Primary Endpoint Of Change In Als Functional Rating Scale-Revised - 8KBenzinga Newsdesk - Feb 16, 2024, 8:07AM
Monday, February 12, 2024
Wednesday, February 07, 2024
Monday, January 08, 2024
Wednesday, December 13, 2023
Monday, November 20, 2023
Wednesday, November 08, 2023
- Denali Therapeutics shares are trading lower after the company reported a year-over-year decrease in Q3 revenue results.Benzinga Newsdesk - Nov 8, 2023, 12:12PM
- Where Denali Therapeutics Stands With AnalystsBenzinga Insights - Nov 8, 2023, 9:00AM
- Wedbush Reiterates Outperform on Denali Therapeutics, Maintains $31 Price TargetBenzinga Newsdesk - Nov 8, 2023, 8:53AM
Tuesday, November 07, 2023
Friday, November 03, 2023
Tuesday, October 24, 2023
Tuesday, October 03, 2023
Thursday, September 28, 2023
Tuesday, September 19, 2023
Wednesday, September 06, 2023
- Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: AnalystVandana Singh - Sep 6, 2023, 2:45PM
- Denali Therapeutics shares are trading higher after B. Riley Securities initiated coverage on the stock with a Buy rating and $38 price target.Benzinga Newsdesk - Sep 6, 2023, 1:19PM
- Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023Benzinga Insights - Sep 6, 2023, 11:00AM
- B. Riley Securities Initiates Coverage On Denali Therapeutics with Buy Rating, Announces Price Target of $38Benzinga Newsdesk - Sep 6, 2023, 8:37AM
Thursday, August 31, 2023
- HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $105 Price TargetBenzinga Newsdesk - Aug 31, 2023, 10:08AM
- Analyst Expectations for Denali Therapeutics's FutureBenzinga Insights - Aug 31, 2023, 10:00AM
- Cantor Fitzgerald Reiterates Overweight on Denali Therapeutics, Maintains $85 Price TargetBenzinga Newsdesk - Aug 31, 2023, 9:23AM
Wednesday, August 30, 2023
Tuesday, August 22, 2023
Tuesday, August 15, 2023
Thursday, August 10, 2023
Wednesday, August 09, 2023
- Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $31Benzinga Newsdesk - Aug 9, 2023, 3:48PM
- Denali Therapeutics shares are trading lower after the company reported Q2 financial results.Benzinga Newsdesk - Aug 9, 2023, 11:26AM
- HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $105 Price TargetBenzinga Newsdesk - Aug 9, 2023, 6:45AM